21 results
Thumbnail

D2.294 - Allergic contact dermatitis unit at Hospital Joan XXIII (Tarragona, Spain): descriptive analysis 2022 - 2023

Thumbnail

D2.295 - Characterization of Treatment-Refractory Chronic Urticaria: A Large-Scale Retrospective Analysis of Clinical and Laboratory Parameters

Thumbnail

D2.296 - Allergic contact dermatitis caused by a oxybutynin in a transdermal patch

Thumbnail

D2.297 - SEP-631: A Novel Selective and Potent Oral MRGPRX2 Inhibitor for the Treatment of Chronic Spontaneous Urticaria

Thumbnail

D2.299 - A novel synthetic molecule LN49 suppressed oxidative stress and inflammation in skin epithelial and fibroblast cells via activating Nrf-2 signaling pathway

Thumbnail

D2.300 - Fixed Drug Eruption related to the use of NSAIDs

Thumbnail

D2.302 - Non - immediate hypersensitivity to oxybutynin, first confirmed case with lymphocyte transformation test

Thumbnail

D2.303 - Blistering Discovery: A Rare Case of Toxic Epidermal Necrolysis Triggered by Carboplatin and Radiotherapy

Thumbnail

D2.304 - Transepidermal Water Loss in Atopic Diseases

Thumbnail

D2.305 - Acute generalized exanthematous pustulosis due to iohexol with tolerance to iobitridol

Thumbnail

D2.306 - Sodium dodecyl sulfate impairs the skin epithelial barrier by inducing oxidative stress in human skin

Thumbnail

D2.307 - Diagnostic characterization of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): Case series from a tertiary care hospital and literature review

Thumbnail

D2.308 - Evaluation of ChatGPT Responses to Frequently Asked Questions by Parents of Children with Atopic Dermatitis

Thumbnail

D3.389 - Deep Learning-Based Real-Time Identification of Wheezing in Lung Sounds: Applications in Disease Prediction and Early Intervention

Thumbnail

D3.390 - Rationale and Design for ALPHA-ORBIT: a phase 3 trial of navenibart, a monoclonal antibody inhibitor of plasma kallikrein for participants with hereditary angioedema (HAE)

Thumbnail

D3.391 - Results from the ALPHA-STAR Trial, a Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Navenibart in Participants with Hereditary Angioedema (HAE)

Thumbnail

D3.392 - What information and education is crucial for people with food allergies?

Thumbnail

D3.393 - Daily life with a peanut allergy, as a young adult- an interview study

Thumbnail

D3.394 - Anxiety Associated with Parenteral On-Demand Treatment for Hereditary Angioedema Attacks in Patients from Italy

Thumbnail

D3.395 - Evaluation for suspected penicillin allergy - the patient perspective